Epiminder Limited
EPI.ASXHealth Care
Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy. Epiminder's groundbreaking Minder system is a sub-scalp device for continuous monitoring of electrographic brain activity an
Market Data
$0.400
+0.0%$85.6M
-100000.0x
$-0.329
0.00%
-0.6%
Latest Earnings
1HFY26 Appendix 4D and Financial Report
25 February 2026
Epiminder Limited reported a half-year loss of $21.7M (1HFY26) compared to $15.4M in the prior year, reflecting increased R&D and commercialisation spending as the company entered its critical commercialisation phase following a successful $125M IPO in December 2025. Key milestones include FDA approval of the Minder device in April 2025, commencement of the DETECT clinical program with 9 leading US medical centres, the first US implant in January 2026, and a 23% Medicare reimbursement uplift to US$27,700. The company is well-capitalised with $89.5M cash post-IPO after settling a $15.8M historical R&D claim with the ATO. Key points: FDA approval of Minder device achieved in April 2025, marking the only FDA-approved remote monitoring device for epilepsy; Successfully raised $125M through IPO completed 1 December 2025, providing substantial capital for commercialisation plan and strengthening balance sheet; DETECT clinical program commenced with 9 leading innovative US medical centres signed up to demonstrate superiority of continuous EEG monitoring vs standard of care (target 210 implants over 18 months)
Recent Announcements
1HFY26 Appendix 4D and Financial Report
Epiminder Limited reported a half-year loss of $21.7M (1HFY26) compared to $15.4M in the prior year, reflecting increased R&D and commercialisation spending as the company entered its critical commercialisation phase following a successful $125M IPO in December 2025. Key milestones include FDA approval of the Minder device in April 2025, commencement of the DETECT clinical program with 9 leading US medical centres, the first US implant in January 2026, and a 23% Medicare reimbursement uplift to US$27,700. The company is well-capitalised with $89.5M cash post-IPO after settling a $15.8M historical R&D claim with the ATO. Key points: FDA approval of Minder device achieved in April 2025, marking the only FDA-approved remote monitoring device for epilepsy; Successfully raised $125M through IPO completed 1 December 2025, providing substantial capital for commercialisation plan and strengthening balance sheet; DETECT clinical program commenced with 9 leading innovative US medical centres signed up to demonstrate superiority of continuous EEG monitoring vs standard of care (target 210 implants over 18 months)
Get real-time alerts for EPI
Receive AI-powered earnings summaries and instant notifications when Epiminder Limited releases results.
Register Free